schliessen

Filtern

 

Bibliotheken

Cover Image

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

Summary Background Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. We aimed to assess effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension. Methods In this multicentre,... Full description

Journal Title: The Lancet (British edition) 2010, Vol.376 (9756), p.1903-1909
Main Author: Esler, Murray D
Other Authors: Krum, Henry , Sobotka, Paul A , Schlaich, Markus P , Schmieder, Roland E , Böhm, Michael
Format: Electronic Article Electronic Article
Language: English
Subjects:
Abridged Index Medicus
Aged
Antihypertensive Agents - therapeutic use
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Blood and lymphatic vessels
Blood pressure
Blood Pressure Monitoring, Ambulatory
Cardiology. Vascular system
Care and treatment
Compliance
Control
Denervation
Diabetes
Disease
Essential hypertension
Female
General aspects
Humans
Hypertension
Hypertension - diagnosis
Hypertension - drug therapy
Hypertension - surgery
Internal Medicine
Kidney - innervation
Male
Medical imaging
Medical sciences
Middle Aged
Mortality
Physiological aspects
Prospective Studies
Radio frequency
Sympathectomy
Veins & arteries
Quelle: Alma/SFX Local Collection
Publisher: Kidlington: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_816386473
title: Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
format: Article
creator:
  • Esler, Murray D
  • Krum, Henry
  • Sobotka, Paul A
  • Schlaich, Markus P
  • Schmieder, Roland E
  • Böhm, Michael
subjects:
  • Abridged Index Medicus
  • Aged
  • Antihypertensive Agents - therapeutic use
  • Arterial hypertension. Arterial hypotension
  • Biological and medical sciences
  • Blood and lymphatic vessels
  • Blood pressure
  • Blood Pressure Monitoring, Ambulatory
  • Cardiology. Vascular system
  • Care and treatment
  • Compliance
  • Control
  • Denervation
  • Diabetes
  • Disease
  • Essential hypertension
  • Female
  • General aspects
  • Humans
  • Hypertension
  • Hypertension - diagnosis
  • Hypertension - drug therapy
  • Hypertension - surgery
  • Internal Medicine
  • Kidney - innervation
  • Male
  • Medical imaging
  • Medical sciences
  • Middle Aged
  • Mortality
  • Physiological aspects
  • Prospective Studies
  • Radio frequency
  • Sympathectomy
  • Veins & arteries
ispartof: The Lancet (British edition), 2010, Vol.376 (9756), p.1903-1909
description: Summary Background Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. We aimed to assess effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension. Methods In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (≥150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months. Primary analysis included all patients remaining in follow-up at 6 months. This trial is registered with ClinicalTrials.gov , number NCT00888433. Findings 106 (56%) of 190 patients screened for eligibility were randomly allocated to renal denervation (n=52) or control (n=54) groups between June 9, 2009, and Jan 15, 2010. 49 (94%) of 52 patients who underwent renal denervation and 51 (94%) of 54 controls were assessed for the primary endpoint at 6 months. Office-based blood pressure measurements in the renal denervation group reduced by 32/12 mm Hg (SD 23/11, baseline of 178/96 mm Hg, p
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.8077204
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_816386473
sourceformatXML
sourcesystemPC
galeidA243730039
sourcerecordidA243730039
originalsourceidFETCH-LOGICAL-1627t-6b94226897bff8b5252b2ef0a6028f59ce97ffd81059d8a1bb3cf3e7072b25f3
addsrcrecordideNqFknFr1DAYxoso7px-BCUo4gZ2Jk2btArKGOqEoeDuD_8LafrmLjNNzyQ3uc_glza9O093CKOQtm9-z8ObvE-WPSb4hGDCXl1iUuKcccqOCD5mBaZN3tzJJqTkZV6V_NvdbLJDDrIHIVxhjEuGq_vZQUFwQzFlk-zXV3DSorDqFzLOIRqFOnDgr2U0g0PGoVQ34GJAP02co-hBxj795x6CCVG6iOarBfgILoyKo-kc0GWys0aZuELn0895gabeSHv8GknkpeuG3gTokBpc9IO16TOO-w-ze1raAI-278Ns-uH99Ow8v_jy8dPZ6UVOWMFjztqmLApWN7zVum6roiraAjSWDBe1rhoFDde6qwmumq6WpG2p0hQ45omrND3MXmxsF374sYQQRWpHgbXSwbAMoiaM1qzkNJFP98irYenTfa2hkrCakwQ920AzaUEYp4fopRotxWlRUk5xGk2iTv5DpaeD3qSLAG1S_Ybg5T-CdhmMg5CWYGbzGGZyGcJNvNrgyg8heNBi4U0v_UoQLMbAiHVgxJiGsbQOjBh1T7ZHXLY9dDvVn4Qk4PkWkEFJq9P8lAl_OVphziqeuDd7DaTxr0OUDmrsrW2826ghzf3agBdBpdQp6IwHFUU3mFsd3u45KGucSS1_hxWE3eCICIXAG5PRg-C1Q0N_A4xzA88
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid816416871
display
typearticle
titleRenal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
sourceAlma/SFX Local Collection
creatorEsler, Murray D ; Krum, Henry ; Sobotka, Paul A ; Schlaich, Markus P ; Schmieder, Roland E ; Böhm, Michael
creatorcontribEsler, Murray D ; Krum, Henry ; Sobotka, Paul A ; Schlaich, Markus P ; Schmieder, Roland E ; Böhm, Michael ; Symplicity HTN-2 Investigators
descriptionSummary Background Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. We aimed to assess effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension. Methods In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (≥150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months. Primary analysis included all patients remaining in follow-up at 6 months. This trial is registered with ClinicalTrials.gov , number NCT00888433. Findings 106 (56%) of 190 patients screened for eligibility were randomly allocated to renal denervation (n=52) or control (n=54) groups between June 9, 2009, and Jan 15, 2010. 49 (94%) of 52 patients who underwent renal denervation and 51 (94%) of 54 controls were assessed for the primary endpoint at 6 months. Office-based blood pressure measurements in the renal denervation group reduced by 32/12 mm Hg (SD 23/11, baseline of 178/96 mm Hg, p<0·0001), whereas they did not differ from baseline in the control group (change of 1/0 mm Hg [21/10], baseline of 178/97 mm Hg, p=0·77 systolic and p=0·83 diastolic). Between-group differences in blood pressure at 6 months were 33/11 mm Hg (p<0·0001). At 6 months, 41 (84%) of 49 patients who underwent renal denervation had a reduction in systolic blood pressure of 10 mm Hg or more, compared with 18 (35%) of 51 controls (p<0·0001). We noted no serious procedure-related or device-related complications and occurrence of adverse events did not differ between groups; one patient who had renal denervation had possible progression of an underlying atherosclerotic lesion, but required no treatment. Interpretation Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients. Funding Ardian.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(10)62039-9
3PMID: 21093036
4CODEN: LANCAO
languageeng
publisherKidlington: Elsevier Ltd
subjectAbridged Index Medicus ; Aged ; Antihypertensive Agents - therapeutic use ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood pressure ; Blood Pressure Monitoring, Ambulatory ; Cardiology. Vascular system ; Care and treatment ; Compliance ; Control ; Denervation ; Diabetes ; Disease ; Essential hypertension ; Female ; General aspects ; Humans ; Hypertension ; Hypertension - diagnosis ; Hypertension - drug therapy ; Hypertension - surgery ; Internal Medicine ; Kidney - innervation ; Male ; Medical imaging ; Medical sciences ; Middle Aged ; Mortality ; Physiological aspects ; Prospective Studies ; Radio frequency ; Sympathectomy ; Veins & arteries
ispartofThe Lancet (British edition), 2010, Vol.376 (9756), p.1903-1909
rights
0Elsevier Ltd
12010 Elsevier Ltd
22015 INIST-CNRS
3Copyright © 2010 Elsevier Ltd. All rights reserved.
4COPYRIGHT 2010 Elsevier B.V.
5Copyright Elsevier Limited Dec 4-Dec 10, 2010
lds50peer_reviewed
citedbyFETCH-LOGICAL-1627t-6b94226897bff8b5252b2ef0a6028f59ce97ffd81059d8a1bb3cf3e7072b25f3
citesFETCH-LOGICAL-1627t-6b94226897bff8b5252b2ef0a6028f59ce97ffd81059d8a1bb3cf3e7072b25f3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23507657$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21093036$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Esler, Murray D
1Krum, Henry
2Sobotka, Paul A
3Schlaich, Markus P
4Schmieder, Roland E
5Böhm, Michael
6Symplicity HTN-2 Investigators
title
0Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
1The Lancet (British edition)
addtitleLancet
descriptionSummary Background Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. We aimed to assess effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension. Methods In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (≥150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months. Primary analysis included all patients remaining in follow-up at 6 months. This trial is registered with ClinicalTrials.gov , number NCT00888433. Findings 106 (56%) of 190 patients screened for eligibility were randomly allocated to renal denervation (n=52) or control (n=54) groups between June 9, 2009, and Jan 15, 2010. 49 (94%) of 52 patients who underwent renal denervation and 51 (94%) of 54 controls were assessed for the primary endpoint at 6 months. Office-based blood pressure measurements in the renal denervation group reduced by 32/12 mm Hg (SD 23/11, baseline of 178/96 mm Hg, p<0·0001), whereas they did not differ from baseline in the control group (change of 1/0 mm Hg [21/10], baseline of 178/97 mm Hg, p=0·77 systolic and p=0·83 diastolic). Between-group differences in blood pressure at 6 months were 33/11 mm Hg (p<0·0001). At 6 months, 41 (84%) of 49 patients who underwent renal denervation had a reduction in systolic blood pressure of 10 mm Hg or more, compared with 18 (35%) of 51 controls (p<0·0001). We noted no serious procedure-related or device-related complications and occurrence of adverse events did not differ between groups; one patient who had renal denervation had possible progression of an underlying atherosclerotic lesion, but required no treatment. Interpretation Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients. Funding Ardian.
subject
0Abridged Index Medicus
1Aged
2Antihypertensive Agents - therapeutic use
3Arterial hypertension. Arterial hypotension
4Biological and medical sciences
5Blood and lymphatic vessels
6Blood pressure
7Blood Pressure Monitoring, Ambulatory
8Cardiology. Vascular system
9Care and treatment
10Compliance
11Control
12Denervation
13Diabetes
14Disease
15Essential hypertension
16Female
17General aspects
18Humans
19Hypertension
20Hypertension - diagnosis
21Hypertension - drug therapy
22Hypertension - surgery
23Internal Medicine
24Kidney - innervation
25Male
26Medical imaging
27Medical sciences
28Middle Aged
29Mortality
30Physiological aspects
31Prospective Studies
32Radio frequency
33Sympathectomy
34Veins & arteries
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2010
recordtypearticle
recordideNqFknFr1DAYxoso7px-BCUo4gZ2Jk2btArKGOqEoeDuD_8LafrmLjNNzyQ3uc_glza9O093CKOQtm9-z8ObvE-WPSb4hGDCXl1iUuKcccqOCD5mBaZN3tzJJqTkZV6V_NvdbLJDDrIHIVxhjEuGq_vZQUFwQzFlk-zXV3DSorDqFzLOIRqFOnDgr2U0g0PGoVQ34GJAP02co-hBxj795x6CCVG6iOarBfgILoyKo-kc0GWys0aZuELn0895gabeSHv8GknkpeuG3gTokBpc9IO16TOO-w-ze1raAI-278Ns-uH99Ow8v_jy8dPZ6UVOWMFjztqmLApWN7zVum6roiraAjSWDBe1rhoFDde6qwmumq6WpG2p0hQ45omrND3MXmxsF374sYQQRWpHgbXSwbAMoiaM1qzkNJFP98irYenTfa2hkrCakwQ920AzaUEYp4fopRotxWlRUk5xGk2iTv5DpaeD3qSLAG1S_Ybg5T-CdhmMg5CWYGbzGGZyGcJNvNrgyg8heNBi4U0v_UoQLMbAiHVgxJiGsbQOjBh1T7ZHXLY9dDvVn4Qk4PkWkEFJq9P8lAl_OVphziqeuDd7DaTxr0OUDmrsrW2826ghzf3agBdBpdQp6IwHFUU3mFsd3u45KGucSS1_hxWE3eCICIXAG5PRg-C1Q0N_A4xzA88
startdate2010
enddate2010
creator
0Esler, Murray D
1Krum, Henry
2Sobotka, Paul A
3Schlaich, Markus P
4Schmieder, Roland E
5Böhm, Michael
general
0Elsevier Ltd
1Elsevier
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
100TT
110TZ
120U~
133V.
147QL
157QP
167RV
177TK
187U7
197U9
207X7
217XB
2288A
2388C
2488E
2588G
2688I
278AF
288AO
298C1
308C2
318FE
328FH
338FI
348FJ
358FK
368G5
37ABUWG
38AN0
39ASE
40AZQEC
41BBNVY
42BEC
43BENPR
44BHPHI
45C1K
46DWQXO
47FPQ
48FYUFA
49GHDGH
50GNUQQ
51GUQSH
52H94
53HCIFZ
54K6X
55K9-
56K9.
57KB0
58KB~
59LK8
60M0R
61M0S
62M0T
63M1P
64M2M
65M2O
66M2P
67M7N
68M7P
69MBDVC
70NAPCQ
71PQEST
72PQQKQ
73PQUKI
74Q9U
75S0X
767X8
sort
creationdate2010
titleRenal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
authorEsler, Murray D ; Krum, Henry ; Sobotka, Paul A ; Schlaich, Markus P ; Schmieder, Roland E ; Böhm, Michael
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1627t-6b94226897bff8b5252b2ef0a6028f59ce97ffd81059d8a1bb3cf3e7072b25f3
rsrctypearticles
prefilterarticles
languageeng
creationdate2010
topic
0Abridged Index Medicus
1Aged
2Antihypertensive Agents - therapeutic use
3Arterial hypertension. Arterial hypotension
4Biological and medical sciences
5Blood and lymphatic vessels
6Blood pressure
7Blood Pressure Monitoring, Ambulatory
8Cardiology. Vascular system
9Care and treatment
10Compliance
11Control
12Denervation
13Diabetes
14Disease
15Essential hypertension
16Female
17General aspects
18Humans
19Hypertension
20Hypertension - diagnosis
21Hypertension - drug therapy
22Hypertension - surgery
23Internal Medicine
24Kidney - innervation
25Male
26Medical imaging
27Medical sciences
28Middle Aged
29Mortality
30Physiological aspects
31Prospective Studies
32Radio frequency
33Sympathectomy
34Veins & arteries
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Esler, Murray D
1Krum, Henry
2Sobotka, Paul A
3Schlaich, Markus P
4Schmieder, Roland E
5Böhm, Michael
6Symplicity HTN-2 Investigators
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9News PRO
10Pharma and Biotech Premium PRO
11Global News & ABI/Inform Professional
12ProQuest Central (Corporate)
13Bacteriology Abstracts (Microbiology B)
14Calcium & Calcified Tissue Abstracts
15Nursing & Allied Health Database
16Neurosciences Abstracts
17Toxicology Abstracts
18Virology and AIDS Abstracts
19Health & Medical Collection
20ProQuest Central (purchase pre-March 2016)
21Biology Database (Alumni Edition)
22Healthcare Administration Database (Alumni)
23Medical Database (Alumni Edition)
24Psychology Database (Alumni)
25Science Database (Alumni Edition)
26STEM Database
27ProQuest Pharma Collection
28Public Health Database
29Lancet Titles
30ProQuest SciTech Collection
31ProQuest Natural Science Collection
32Hospital Premium Collection
33Hospital Premium Collection (Alumni Edition)
34ProQuest Central (Alumni) (purchase pre-March 2016)
35Research Library (Alumni Edition)
36ProQuest Central (Alumni Edition)
37British Nursing Database
38British Nursing Index
39ProQuest Central Essentials
40Biological Science Collection
41eLibrary
42ProQuest Central
43Natural Science Collection
44Environmental Sciences and Pollution Management
45ProQuest Central Korea
46British Nursing Index (BNI) (1985 to Present)
47Health Research Premium Collection
48Health Research Premium Collection (Alumni)
49ProQuest Central Student
50Research Library Prep
51AIDS and Cancer Research Abstracts
52SciTech Premium Collection
53British Nursing Index
54Consumer Health Database (Alumni Edition)
55ProQuest Health & Medical Complete (Alumni)
56Nursing & Allied Health Database (Alumni Edition)
57ProQuest Newsstand Professional
58ProQuest Biological Science Collection
59Consumer Health Database
60Health & Medical Collection (Alumni Edition)
61Healthcare Administration Database
62Medical Database
63Psychology Database
64Research Library
65Science Database
66Algology Mycology and Protozoology Abstracts (Microbiology C)
67Biological Science Database
68Research Library (Corporate)
69Nursing & Allied Health Premium
70ProQuest One Academic Eastern Edition
71ProQuest One Academic
72ProQuest One Academic UKI Edition
73ProQuest Central Basic
74SIRS Editorial
75MEDLINE - Academic
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Esler, Murray D
1Krum, Henry
2Sobotka, Paul A
3Schlaich, Markus P
4Schmieder, Roland E
5Böhm, Michael
aucorpSymplicity HTN-2 Investigators
formatjournal
genrearticle
ristypeJOUR
atitleRenal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
jtitleThe Lancet (British edition)
addtitleLancet
date2010
risdate2010
volume376
issue9756
spage1903
epage1909
pages1903-1909
issn0140-6736
eissn1474-547X
codenLANCAO
abstractSummary Background Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. We aimed to assess effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension. Methods In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (≥150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months. Primary analysis included all patients remaining in follow-up at 6 months. This trial is registered with ClinicalTrials.gov , number NCT00888433. Findings 106 (56%) of 190 patients screened for eligibility were randomly allocated to renal denervation (n=52) or control (n=54) groups between June 9, 2009, and Jan 15, 2010. 49 (94%) of 52 patients who underwent renal denervation and 51 (94%) of 54 controls were assessed for the primary endpoint at 6 months. Office-based blood pressure measurements in the renal denervation group reduced by 32/12 mm Hg (SD 23/11, baseline of 178/96 mm Hg, p<0·0001), whereas they did not differ from baseline in the control group (change of 1/0 mm Hg [21/10], baseline of 178/97 mm Hg, p=0·77 systolic and p=0·83 diastolic). Between-group differences in blood pressure at 6 months were 33/11 mm Hg (p<0·0001). At 6 months, 41 (84%) of 49 patients who underwent renal denervation had a reduction in systolic blood pressure of 10 mm Hg or more, compared with 18 (35%) of 51 controls (p<0·0001). We noted no serious procedure-related or device-related complications and occurrence of adverse events did not differ between groups; one patient who had renal denervation had possible progression of an underlying atherosclerotic lesion, but required no treatment. Interpretation Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients. Funding Ardian.
copKidlington
pubElsevier Ltd
pmid21093036
doi10.1016/S0140-6736(10)62039-9